Results 101 to 110 of about 47,032 (177)

Nuclear medicine in endocrine tumours [PDF]

, 2011
C
Peremans, Kathelijne, Van De Wiele, Christophe   +1 more
core   +2 more sources

Scalability study on [133La]LaCl3 production with a focus on potential clinical applications

EJNMMI Radiopharmacy and Chemistry
Background In recent years, targeted alpha therapy has gained importance in the clinics, and in particular, the alpha-emitter 225Ac plays a fundamental role in this clinical development.
Santiago Andrés Brühlmann, Martin Walther, Magdalena Kerstin Blei, Constantin Mamat, Klaus Kopka, Robert Freudenberg, Martin Kreller   +6 more
doaj   +1 more source

Comparison of technetium-99m IgG with technetium-99m red blood cells labeling in cardiac blood-pool scintigraphy: A preliminary study [PDF]

, 2011
This first clinical prospective study was conducted to use of technetium-99m immunoglobulin G (99mTc-IgG) as compared with autologous 99mTc-red blood cells (RBC) in gated blood pool ventriculography.
Amini, A., Ansari, M., Asli, I.N., Assadi, M., Barekat, M., Jallalat, S., Javadi, H., Semnani, S.   +7 more
core  

Development and Study of {99m}Tc-1-Thio-D-glucose for Visualization of Malignant Tumors [PDF]

, 2017
The preclinical studies of {99m}Tc-1-Thio-D-glucose, a new tumor-seeking agent based on technetium-99mlabeled glucose derivative, were conducted, and the feasibility of using this radiopharmaceutical for tumor visualization was studied.
Bragina, Olga Dmitrievna, Chernov, Vladimir Ivanovich, Ilina, Elena Sergeevna, Medvedeva, Anna Aleksndrovna, Rogov, Alexander Sergeyevich, Sinilkin, Ivan Gennadjevich, Skuridin, Viktor Sergeyevich, Stasyuk, Elena Sergeyevna, Zeltchan, R. V.   +8 more
core   +1 more source

Preparation and Characterization of Zirconia Nanomaterial as a Molybdenum-99 Adsorbent

Atom Indonesia, 2017
The present study deals with the synthesis and characterization of ZrO2 nanomaterial which can be used as an adsorbent for Molybdenum-99 (99Mo). The adsorbent can potentially be utilized as the material for 99Mo/99mTc generator column.
M Marlina, E. Sarmini, H Herlina, S Sriyono, I. Saptiama, H. Setiawan, K Kadarisman   +6 more
doaj   +1 more source

It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies

EJNMMI Radiopharmacy and Chemistry
Background Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years.
Johanna Trommer, Martin Ullrich, Falco Reissig, Santiago Andres Brühlmann, Anne-Kathrin Nitt-Weber, Zbynek Novy, Katarina Hajduova, Daniela Kurfurstova, Romana Hendrychova, Jan Bouchal, Milos Petrik, Christin Neuber, Wiebke Sihver, Sven Stadlbauer, Jens Pietzsch, Martin Kreller, Klaus Kopka, Constantin Mamat, Kristof Zarschler   +18 more
doaj   +1 more source

Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells

OncoImmunology
The fibroblast activation protein alpha (FAPα) is overexpressed in the tumor microenvironment of most solid cancers and, in some cases, in cancer cells, making it an interesting target for theranostic applications.
Hugo Boutier, Jürgen Kogler, Liliana R. Loureiro, Christin Neuber, Nicole Berndt, Claudia Arndt, Sven Stadlbauer, Holger Stephan, Anja Feldmann, Klaus Kopka, Christoph E. Hagemeyer, Michael Bachmann   +11 more
doaj   +1 more source

Synthesis of Nano-α-Al2O3 for 99Mo Adsorbent

Atom Indonesia, 2018
The fission-product 99Mo, having a high specific activity, is commonly used in alumina-based 99Mo/99mTc generator. Due to the limitation on the use of fission-product 99Mo, an alternative route for 99Mo production, namely activation of natural molybdenum
K Kadarisman, S Sriyono, A Abidin, E. Lestari, M Marlina, I. Saptiama, H. Setiawan   +6 more
doaj   +1 more source

Focal Spot, Summer 1999 [PDF]

, 1999
https://digitalcommons.wustl.edu/focal_spot_archives/1082/thumbnail ...

core   +1 more source

Introduction of the New Center for Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf

Instruments, 2019
A new Center for Radiopharmaceutical Cancer Research was established at the Helmholtz-Zentrum Dresden-Rossendorf in order to centralize radionuclide production, radiopharmaceutical production and the chemical and biochemical research facilities.
M. Kreller, H. Pietzsch, M. Walther, H. Tietze, P. Kaever, T. Kniess, F. Füchtner, J. Steinbach, S. Preusche   +8 more
semanticscholar   +1 more source